Is Alibaba Group Holding Ltd. A Long Term Stock?

Alibaba’s management continues to reassure investors on the stock’s potential; however, analysts do not seem convinced

During this time when Alibaba Group Holding Ltd. is witnessing serious growth issues, the management of the company is doing their best to provide assurances to shareholders. As reported by Reuters, Joseph C. Tsai, Executive Vice Chairman of the company has said that the management is aware of the low share price level, and added that Alibaba’s fundamentals are much stronger now compared to the time of its initial public offering last year.

Alibaba’s stock price performance shows an entirely different picture, according to recent Alibaba stock news. As the company is reaching one year of its IPO, the stock is declining reaching a price less than its IPO levels. Baba stock closed at $64.90 yesterday, with a 52-week high and low $120 and $58, respectively. The e-commerce giant has a market capitalization of nearly $153.20 billion. Performance of stock shows that the company shares faced the worst ham this year. The stock has shack over 38% this year, according to Alibaba stock analysis.

On Monday, the company established that as consumer spending pull back on a Chinese economy slowdown, the Chinese company’s GMV is expected to drop below estimations. This also applies to Alibaba’s second quarter projections for FY16; while, several experts have warned that the country’s economic slowdown might affect volumes further than the second quarter.

The forecast comes out to be true as experts moves on to reduce the target prices yesterday on baba stock. However, in spite of substantial cuts to price targets, analysts reiterated their Buy rating on stock.

Youssef Squali, an analyst at Cantor Fitzgerald reduced his price target on e-commerce giant’s stock to $88 from previous $95, while reiterated a Buy rating. Likewise, Cheng Cheng, analyst at Pacific Crest, rated it a Buy, but with reduced price target from $94 to $80.

Remarkably, both these downgrades show a short term view. Analysts are optimistic on long term prospects of the company, and expect it gaining substantial gains for shareholders having long positions. Mr. Cheng also stated in his research note: “Domestic macro and emerging market currency fluctuation prompt lower estimates. We still view Alibaba’s prospects positively long-term, but volatility and limited visibility in both China macro and emerging market currency negatively impact our confidence in the short-term.”

Most experts who measure Alibaba’s long term performance agree with the idea above and are still bullish on Alibaba stock. Almost 52 analysts at Bloomberg covered the stock, out of which 45 gave it a Buy, 5 recommend a Hold, while only 2 suggests a Sell. The twelve month average price target is $94.81, almost 50% of upside potential to closing price of $64.90.

Jefferies Reiterate Buy Rating On CVS Health Stock

CVS reports strong quarterly results for 2QFY15, leading to a positive outlook on the stock from Jefferies

CVS Health Corp. announced its second quarter results for fiscal year 2015 earlier last week. However, the stock declined during the trading session, after the earnings release, it started to recover the next day. The earnings announcement resulted in many sell side firm to revise their viewpoint on the company’s stock. Here is what Jefferies think about the stock.

CVS Health Corp. was able to report adjusted earnings of $1.22 per share for the recent quarter, surpassing analysts’ estimates by almost 2.6 cents. The company beat analysts’ expectation for the fifth time in a row. The figure enhanced by $0.09 year over year, as adjusted earnings for the prior year quarter was $1.13 per share.

The revenue for the company came in at $37.17 billion, despite of strong growth, it fell short of consensus estimate by 0.01%, and this was the first revenue for the company in past 13 quarters. The revenue figure for the period reflected a year over year growth of over 7%.

Jefferies has given the stock a Buy rating, with a price target of $125. The firm’s analyst having coverage on CVS stock believes more than expected retail, strong growth in Rx, and a robust beginning to pharmacy benefit manager for the current year is the main reason for the bullish stance on the company’s stock. For pharmacy benefit manager, CVS has announced gross latest business wins of around $12 billion up till now, together with $11 billion in net wins. Adding to this, the specialty Rx growth of 28% has surpassed growth in the division.

Investors’ negative reaction after the earnings announcement was primarily because of the reduction in guidance by the company’s management for third quarter. However, according to analysts it should not bother investors, as CVS has much of its emphasis on acquisition this year. CVS Health has also cut $1 billion from the amount due for share buyback to support funding of its Omnicare and Target Pharmacy acquisition.

The $125 price target given by the sell side firm uses a 20.5x of multiple for price to earnings ratio, using the expected figures for FY16, according to CVS stock analysis.

The Street is still bullish on company’ stock. Almost 28 analysts at Bloomberg covered the stock, 25 gave it a Buy, 3 rate it a Hold, while none suggests it a Sell rating, as reported by CVS stock news. The consensus price target is $119.35, which shows a 7.5% of return potential compared to current closing price.

RBC Capital Markets analyst Fran G. Morgan is most bullish with an Outperform rating and target price of $132 on the stock, while Morgan Stanley analyst Ricky Goldwasser is the most bearish with $111 target price and Overweight rating.